Tags

Type your tag names separated by a space and hit enter

The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.
Br J Cancer 2007; 97(8):1084-9BJ

Abstract

The purpose of this study was to investigate the cardioprotective effect of the semisynthetic flavonoid 7-monohydroxyethylrutoside (monoHER) on doxorubicin (DOX)-induced cardiotoxicity in a phase II study in patients with metastatic cancer. Eight patients with metastatic cancer were treated with DOX preceded by a 10 min i.v. infusion of 1500 mg m(-2) monoHER. Five patients were examined by endomyocardial biopsy after reaching a cumulative dose of 300 mg m(-2). Histopathological changes in the cardiomyocytes (Billingham score) were compared with those described in literature for patients treated with DOX only. The mean biopsy score of the patients was higher (2.7) than the mean score (1.4) of historical data of patients who received similar cumulative doses of DOX. Although there is a considerable variability in few investigated patients, it was indicative that monoHER enhanced DOX-induced cardiotoxicity. However, the antitumour activity of DOX seemed better than expected: three of the four patients with metastatic soft-tissue sarcoma had a partial remission and the fourth patient stable disease. It is likely that the relatively high dose of monoHER is responsible for the lack of cardioprotection and for the high response rate in patients with soft-tissue sarcoma possibly by depleting the glutathione defense system in both heart and tumour.

Authors+Show Affiliations

Department of Medical Oncology, 2 PK BR 010, VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands. ame.bruynzeel@vumc.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17940501

Citation

Bruynzeel, A M E., et al. "The Effect of Monohydroxyethylrutoside On Doxorubicin-induced Cardiotoxicity in Patients Treated for Metastatic Cancer in a Phase II Study." British Journal of Cancer, vol. 97, no. 8, 2007, pp. 1084-9.
Bruynzeel AM, Niessen HW, Bronzwaer JG, et al. The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. Br J Cancer. 2007;97(8):1084-9.
Bruynzeel, A. M., Niessen, H. W., Bronzwaer, J. G., van der Hoeven, J. J., Berkhof, J., Bast, A., ... van Groeningen, C. J. (2007). The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. British Journal of Cancer, 97(8), pp. 1084-9.
Bruynzeel AM, et al. The Effect of Monohydroxyethylrutoside On Doxorubicin-induced Cardiotoxicity in Patients Treated for Metastatic Cancer in a Phase II Study. Br J Cancer. 2007 Oct 22;97(8):1084-9. PubMed PMID: 17940501.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. AU - Bruynzeel,A M E, AU - Niessen,H W M, AU - Bronzwaer,J G F, AU - van der Hoeven,J J M, AU - Berkhof,J, AU - Bast,A, AU - van der Vijgh,W J F, AU - van Groeningen,C J, Y1 - 2007/10/16/ PY - 2007/10/18/pubmed PY - 2007/12/15/medline PY - 2007/10/18/entrez SP - 1084 EP - 9 JF - British journal of cancer JO - Br. J. Cancer VL - 97 IS - 8 N2 - The purpose of this study was to investigate the cardioprotective effect of the semisynthetic flavonoid 7-monohydroxyethylrutoside (monoHER) on doxorubicin (DOX)-induced cardiotoxicity in a phase II study in patients with metastatic cancer. Eight patients with metastatic cancer were treated with DOX preceded by a 10 min i.v. infusion of 1500 mg m(-2) monoHER. Five patients were examined by endomyocardial biopsy after reaching a cumulative dose of 300 mg m(-2). Histopathological changes in the cardiomyocytes (Billingham score) were compared with those described in literature for patients treated with DOX only. The mean biopsy score of the patients was higher (2.7) than the mean score (1.4) of historical data of patients who received similar cumulative doses of DOX. Although there is a considerable variability in few investigated patients, it was indicative that monoHER enhanced DOX-induced cardiotoxicity. However, the antitumour activity of DOX seemed better than expected: three of the four patients with metastatic soft-tissue sarcoma had a partial remission and the fourth patient stable disease. It is likely that the relatively high dose of monoHER is responsible for the lack of cardioprotection and for the high response rate in patients with soft-tissue sarcoma possibly by depleting the glutathione defense system in both heart and tumour. SN - 0007-0920 UR - https://www.unboundmedicine.com/medline/citation/17940501/The_effect_of_monohydroxyethylrutoside_on_doxorubicin_induced_cardiotoxicity_in_patients_treated_for_metastatic_cancer_in_a_phase_II_study_ L2 - http://dx.doi.org/10.1038/sj.bjc.6603994 DB - PRIME DP - Unbound Medicine ER -